January 4, 2019 / 11:37 PM / 5 months ago

Appeals court won't revisit decision to nix Acorda patents on MS drug

A federal appeals court on Friday said it would not reconsider a decision invalidating Acorda Therapeutics Inc’s patents on its multiple sclerosis drug Ampyra, in a ruling that clears the way for generic competitors.

The U.S. Court of Appeals for the Federal Circuit denied Acorda’s request that the entire court rehear a September 10 decision that four Acorda patents on Ampyra were invalid because they described obvious ideas.

To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2SHwmjq

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below